Isomorphic Labs Raises $2.1B for AI Drug Discovery

Isomorphic Labs, an Alphabet-backed biotechnology firm, secured $2.1 billion in Series B funding to accelerate its artificial intelligence drug discovery efforts ^[1]. This investment represents the second-largest funding round in the history of the biotechnology industry ^[2]. The company plans to use the capital to scale its AI drug design engine, known as IsoDDE ^[1][3].

The funding will support the movement of the first internal drug candidates into clinical trials by the end of 2026 ^[1]. Isomorphic Labs leverages advanced computational models to predict molecular interactions, aiming to shorten traditional drug development timelines ^[2][3]. This milestone highlights the growing role of sovereign AI investments within the global healthcare sector ^[3].